Preparation of candidates for drugs in psychotic and cognitive therapy (Q77688): Difference between revisions
Jump to navigation
Jump to search
(Changed an Item: Label in wikidata changed) |
(Created claim: summary (P836): The aim of the project is to develop a candidate for an innovative medicine in the therapy of psychotic disorders, in particular the type of Alzheimer’s Disease (“Alzheimer’s”).Dementia of Alzheimer’s & leaves;DATES).The essential functionality of the project will be the pharmacological activity of a new candidate in medicine which is superior in terms of effectiveness and/or security for competitive cures.It should be noted in this regard that...) |
||
| Property / summary | |||
The aim of the project is to develop a candidate for an innovative medicine in the therapy of psychotic disorders, in particular the type of Alzheimer’s Disease (“Alzheimer’s”).Dementia of Alzheimer’s & leaves;DATES).The essential functionality of the project will be the pharmacological activity of a new candidate in medicine which is superior in terms of effectiveness and/or security for competitive cures.It should be noted in this regard that there is currently no pharmacotherapy designed in such a way as to have a dedicated psychotic disorder, such as the type of Alzheimer’s Alzheimer’s, and anti-psychotic drugs, with an indication for the treatment of schizophrenia, are not authorised to treat patients with otting, mainly because of serious adverse effects.Meanwhile, it is estimated that in the world the number of patients with a mental disorder has already exceeded 30 million, and due to the ageing of the population, it is expected to triple over the next 50 years.This project therefore addresses a very important unmet need for medical treatment.The result of the project is to be an innovative molecule, selected for preclinical development on the basis of the results of an extended pharmacological effect, which is then characterised in the clinical trials of phases 1 and 2a, i.e. a Proof-f-concept in a patient with a psychosis, ready for further clinical development and commercialisation in form of bio-taxation.An innovative mechanism of action is an essential element of the therapeutic value of a candidate for a drug that is distinguished from current market competition.Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014). (English) | |||
| Property / summary: The aim of the project is to develop a candidate for an innovative medicine in the therapy of psychotic disorders, in particular the type of Alzheimer’s Disease (“Alzheimer’s”).Dementia of Alzheimer’s & leaves;DATES).The essential functionality of the project will be the pharmacological activity of a new candidate in medicine which is superior in terms of effectiveness and/or security for competitive cures.It should be noted in this regard that there is currently no pharmacotherapy designed in such a way as to have a dedicated psychotic disorder, such as the type of Alzheimer’s Alzheimer’s, and anti-psychotic drugs, with an indication for the treatment of schizophrenia, are not authorised to treat patients with otting, mainly because of serious adverse effects.Meanwhile, it is estimated that in the world the number of patients with a mental disorder has already exceeded 30 million, and due to the ageing of the population, it is expected to triple over the next 50 years.This project therefore addresses a very important unmet need for medical treatment.The result of the project is to be an innovative molecule, selected for preclinical development on the basis of the results of an extended pharmacological effect, which is then characterised in the clinical trials of phases 1 and 2a, i.e. a Proof-f-concept in a patient with a psychosis, ready for further clinical development and commercialisation in form of bio-taxation.An innovative mechanism of action is an essential element of the therapeutic value of a candidate for a drug that is distinguished from current market competition.Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014). (English) / rank | |||
Normal rank | |||
Revision as of 08:53, 4 March 2020
Project in Poland financed by DG Regio
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Preparation of candidates for drugs in psychotic and cognitive therapy |
Project in Poland financed by DG Regio |
Statements
25,796,383.65 zloty
0 references
55,502,648.21 zloty
0 references
46.48 percent
0 references
1 June 2017
0 references
31 December 2023
0 references
ADAMED SP. Z O.O.
0 references
52°23'26.2"N, 20°44'2.0"E
0 references
Celem projektu jest opracowanie kandydata na lek innowacyjny w terapii zaburzeń psychotycznych w otępieniu, szczególnie typu Alzheimerowskiego (ang. Dementia of Alzheimer’s type – DAT). Zasadniczą funkcjonalnością rezultatu projektu będzie aktywność farmakologiczna nowego kandydata na lek, przewyższająca pod względem skuteczności i/lub bezpieczeństwa terapie konkurencyjne. Należy przy tym zaznaczyć, że aktualnie nie istnieje farmakoterapia opracowana w sposób dedykowany zaburzeniom psychotycznym w otępieniu, np. typu Alzheimerowskiego, a leki przeciwpsychotyczne, ze wskazaniem do leczenia schizofrenii, nie są dopuszczone do terapii pacjentów z otępieniem, głównie z uwagi na poważne, zagrażające życiu działania niepożądane. Tymczasem szacuje się, że w skali świata liczba pacjentów z zaburzeniami psychotycznymi w otępieniu przekroczyła już 30 mln i w związku ze starzeniem się społeczeństw, w ciągu najbliższych 50 lat ma ulec potrojeniu. Niniejszy projekt adresuje więc bardzo ważną, niezaspokojoną potrzebę medyczną. Rezultatem projektu ma być innowacyjna molekuła, wyłoniona do rozwoju przedklinicznego na podstawie wyników poszerzonej charakterystyki farmakologicznej, scharakteryzowana następnie w badaniach klinicznych fazy 1 oraz 2a, czyli badaniach proof-of-concept u pacjentów z psychozą w otępieniu, gotowa do dalszego rozwoju klinicznego i komercjalizacji w formie biopartneringu. Istotnym elementem stanowiącym o wartości terapeutycznej opracowywanego kandydata na lek i odróżniającym go od aktualnej konkurencji rynkowej jest jego innowacyjny mechanizm działania. Numer_referencyjny_programu_pomocowego: SA.41471(2015/X) Przeznaczenie_pomocy_publicznej: art. 25 rozporządzenia KE nr 651/2014 z dnia 17 czerwca 2014 r. uznające niektóre rodzaje pomocy za zgodne z rynkiem wewnętrznym w stosowaniu art. 107 i 108 Traktatu (Dz. Urz. UE L 187/1 z 26.06.2014). (Polish)
0 references
The aim of the project is to develop a candidate for an innovative medicine in the therapy of psychotic disorders, in particular the type of Alzheimer’s Disease (“Alzheimer’s”).Dementia of Alzheimer’s & leaves;DATES).The essential functionality of the project will be the pharmacological activity of a new candidate in medicine which is superior in terms of effectiveness and/or security for competitive cures.It should be noted in this regard that there is currently no pharmacotherapy designed in such a way as to have a dedicated psychotic disorder, such as the type of Alzheimer’s Alzheimer’s, and anti-psychotic drugs, with an indication for the treatment of schizophrenia, are not authorised to treat patients with otting, mainly because of serious adverse effects.Meanwhile, it is estimated that in the world the number of patients with a mental disorder has already exceeded 30 million, and due to the ageing of the population, it is expected to triple over the next 50 years.This project therefore addresses a very important unmet need for medical treatment.The result of the project is to be an innovative molecule, selected for preclinical development on the basis of the results of an extended pharmacological effect, which is then characterised in the clinical trials of phases 1 and 2a, i.e. a Proof-f-concept in a patient with a psychosis, ready for further clinical development and commercialisation in form of bio-taxation.An innovative mechanism of action is an essential element of the therapeutic value of a candidate for a drug that is distinguished from current market competition.Reference_reference_programme_aids:SA.41471 (2015/X) _public:Article 25 of Commission Regulation (EC) No 651/2014 of 17 June 2014 declaring certain categories of aid compatible with the internal market in the application of Article 107 and 108 of the Treaty (OJ(OJ LEU L 187/1, 26.06.2014). (English)
0 references
Identifiers
POIR.01.01.01-00-0108/17
0 references